What is it about?
This new technology improves the manufacturing of hexon-modified adenovirus vectors (AdH). AdH vectors are not neutralized by pre-existing Ad5 neutralizing antibodies which are abundant in human populations. This improvement facilitates the use of AdH for gene therapy and vaccine applications.
Featured Image
Why is it important?
This technology facilitates the commercialization of AdH vectors for gene therapy and vaccine products.
Read the Original
This page is a summary of: Identification of a Suppressor Mutation That Improves the Yields of Hexon-Modified Adenovirus Vectors, Journal of Virology, July 2013, ASM Journals,
DOI: 10.1128/jvi.00462-13.
You can read the full text:
Contributors
The following have contributed to this page
